🇯🇵·6h agoIndustry
ロシュ社によるセーファキセルセンナトリウムに関する発表について（第III相IMAGINATION試験の中間解析結果）
Publisher
C
Chugai Pharmaceutical News
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical News
- Region
- Japan
- Scope
- Industry
- Published
- September 24, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical News
Scope: Industry
Related coverage
More related coverage
Merck & Co. (MSD) News/2h ago
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Interpharma Switzerland/6h ago
Klinische Forschung unter Druck: Die Schweiz verliert den Anschluss
Chugai Pharmaceutical/6h ago
Roche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study)
Otsuka Pharmaceutical/12h ago